EQS-News  257  0 Kommentare Sartorius to advance drug discovery and manufacturing with AI in collaboration with NVIDIA

Sartorius to advance drug discovery and manufacturing with AI in collaboration with NVIDIA
 

• Exploring advanced technologies to help bring novel therapies to patients faster
• Sartorius to leverage NVIDIA solutions used in live-cell imaging platforms in drug discovery, and predictive design of manufacturing processes, and more
• Future plans include the creation of foundational models based on Sartorius’ extensive and unique data sets, as well as new predictive AI models, tools, and simulations
• Dialogue with regulatory authorities on the use of AI in life sciences announced

The life science group Sartorius is expanding its multidisciplinary collaboration with NVIDIA to help enable the development of new and better therapies, combining Sartorius’ in-depth knowledge of life sciences and bioprocessing with NVIDIA’s AI-powered computing platforms and software.

"Biological interactions are exceptionally complex. Making better use of data by integrating life science expertise with AI solutions is a promising approach to simplify and accelerate biopharma drug discovery and manufacturing progress. This expanded collaboration with NVIDIA will help result in relevant technological innovations for our customers and ultimately for patients," said Prof. Dr. Oscar-Werner Reif, Chief Technology Officer of Sartorius.

Sartorius has been working with NVIDIA since 2020. The life science group has integrated NVIDIA's technology into its instruments, enabling edge computing applications of its live-cell imaging platform for commercialized AI assays in the lab. The focus of the collaboration has been on developing predictive AI models of stem cell-derived organoids to replace animal models in drug discovery and precision medicine. Sartorius is also using NVIDIA solutions for predictive bioprocess design and simulation tools for manufacturing innovative therapies.